The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia
Abstract
Purpose: Older patients with acute myeloid leukemia (AML) have a high relapse rate after standard chemotherapy. We investigated whether measuring chemotherapy sensitivity by multiparameter flow cytometric minimal residual disease (MFC-MRD) detection has prognostic value in patients older than age 60 years or is simply a surrogate for known age-related risk factors. Patient and Methods: Eight hundred ninety-two unselected patients treated intensively in the United Kingdom National Cancer Research Institute AML16 Trial were assessed prospectively for MFC-MRD during treatment. Eight hundred thirty-three patients had leukemia-associated immunophenotypes (LAIPs) identified by pretreatment screening. Four hundred twenty-seven patients entered complete remission (CR) after one or two courses (designated C1 and C2, respectively) and were MFC-MRD assessable by LAIP detection in CR bone marrow for at least one of these time points. MRD positivity was defined as residual disease detectable by LAIP. Results: MFC-MRD negativity, which was achieved in 51% of patients after C1 (n = 286) and 64% of patients after C2 (n = 279), conferred significantly better 3-year survival from CR (C1: 42% v 26% in MRD-positive patients, P < .001; C2: 38% v 18%, respectively; P < .001) and reduced relapse (C1: 71% v 83% in MRD-positive patients, P < .001; C2: 79% v 91%, respectively; P < .001), with higher risk of early relapse in MRD-positive patients (median time to relapse, 8.5 v 17.1 months, respectively). In multivariable analysis, MRD status at the post-C1 time point independently predicted survival, identifying a subgroup of intermediate-risk patients with particularly poor outcome. However, survival benefit from gemtuzumab ozogamicin was not associated with MFC-MRD chemotherapy sensitivity. Conclusion: Early assessment of treatment response using flow cytometry provides powerful independent prognostic information in older adults with AML, lending support to the incorporation of MRD detection to refine risk stratification and inform clinical trial design in this challenging group of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Self-citationCheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,946
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Lagadinou, E. D., Sach, A., Callahan, K., Rossi, R. M., Neering, S. J., Minhajuddin, M., Ashton, J. M., Pei, S., Grose, V., O’Dwyer, K. M., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2012.12.013 · Cited by 1,399
Age and acute myeloid leukemia
Appelbaum, F. R., Gundacker, H., Head, D. R., Slovak, M. L., Willman, C. L., Godwin, J. E., Anderson, J. E., & Petersdorf, S. H. (2006) · Blood · doi:10.1182/blood-2005-09-3724 · Cited by 1,350
Grimwade, D. (2001) · Blood · doi:10.1182/blood.v98.5.1312 · Cited by 918
Self-citationTherapeutic Advances in Acute Myeloid Leukemia
Burnett, A., Wetzler, M., & Löwenberg, B. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1820 · Cited by 787
Self-citationGale, R. E., Green, C., Allen, C., Mead, A. J., Burnett, A. K., Hills, R. K., & Linch, D. C. (2008) · Blood · doi:10.1182/blood-2007-08-109090 · Cited by 745
Self-citationBurnett, A. K., Hills, R. K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N. H., Yin, J. A. L., Hunter, A., Goldstone, A. H., & Wheatley, K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4310 · Cited by 657
Self-citationKantarjian, H., O'Brien, S., Cortes, J., Giles, F., Faderl, S., Jabbour, E., Garcia‐Manero, G., Wierda, W., Pierce, S., Shan, J., et al. (2006) · Cancer · doi:10.1002/cncr.21723 · Cited by 610
Rubnitz, J. E., Inaba, H., Dahl, G., Ribeiro, R. C., Bowman, W. P., Taub, J., Pounds, S., Razzouk, B. I., Lacayo, N. J., Cao, X., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70090-5 · Cited by 584
Yin, J. A. L., O'Brien, M. A., Hills, R. K., Daly, S. B., Wheatley, K., & Burnett, A. K. (2012) · Blood · doi:10.1182/blood-2012-06-435669 · Cited by 425
Self-citationBurnett, A. K., Russell, N. H., Hills, R. K., Kell, J., Freeman, S., Kjeldsen, L., Hunter, A. E., Yin, J., Craddock, C. F., Dufva, I. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2964 · Cited by 409
Self-citationBecker, H., Marcucci, G., Maharry, K., Radmacher, M. D., Mrózek, K., Margeson, D., Whitman, S. P., Wu, Y.-Z., Schwind, S., Paschka, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1496 · Cited by 338
San Miguel, J. F., Vidriales, M. B., López-Berges, C., Dı́az-Mediavilla, J., Gutiérrez, N., Cañizo, C., Ramos, F., Calmuntia, M. J., Pérez, J. J., González, M., et al. (2001) · Blood · doi:10.1182/blood.v98.6.1746 · Cited by 335
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
Walter, R. B., Appelbaum, F. R., Estey, E. H., & Bernstein, I. D. (2012) · Blood · doi:10.1182/blood-2011-11-325050 · Cited by 321
Krug, U., Röllig, C., Koschmieder, A., Heinecke, A., Sauerland, M. C., Schaich, M., Thiede, C., Kramer, M., Braess, J., Spiekermann, K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62105-8 · Cited by 304
Loken, M. R., Alonzo, T. A., Pardo, L., Gerbing, R. B., Raimondi, S. C., Hirsch, B. A., Ho, P. A., Franklin, J., Cooper, T. M., Gamis, A. S., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408336 · Cited by 297
Green, C. L., Koo, K. K., Hills, R. K., Burnett, A. K., Linch, D. C., & Gale, R. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2501 · Cited by 273
Self-citationKern, W., Voskova, D., Schoch, C., Hiddemann, W., Schnittger, S., & Haferlach, T. (2004) · Blood · doi:10.1182/blood-2004-03-1036 · Cited by 268
Buccisano, F., Maurillo, L., Del Principe, M. I., Del Poeta, G., Sconocchia, G., Lo-Coco, F., Arcese, W., Amadori, S., & Venditti, A. (2012) · Blood · doi:10.1182/blood-2011-08-363291 · Cited by 256
Giles, F. J., Borthakur, G., Ravandi, F., Faderl, S., Verstovsek, S., Thomas, D., Wierda, W., Ferrajoli, A., Kornblau, S., Pierce, S., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06476.x · Cited by 248
Wheatley, K., Brookes, C. L., Howman, A. J., Goldstone, A. H., Milligan, D. W., Prentice, A. G., Moorman, A. V., Burnett, A. K., & on behalf of the United Kingdom National Cancer Research Institute Haematological Oncology Clinical Studies Group and Acute Myeloid Leukaemia Subgroup (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07663.x · Cited by 236
Self-citationFrom single cells to deep phenotypes in cancer
Bendall, S. C., & Nolan, G. P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2283 · Cited by 222
Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia
Inaba, H., Coustan-Smith, E., Cao, X., Pounds, S. B., Shurtleff, S. A., Wang, K. Y., Raimondi, S. C., Onciu, M., Jacobsen, J., Ribeiro, R. C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5323 · Cited by 217
Feller, N., van der Pol, M. A., van Stijn, A., Weijers, G. W. D., Westra, A. H., Evertse, B. W., Ossenkoppele, G. J., & Schuurhuis, G. J. (2004) · Leukemia · doi:10.1038/sj.leu.2403405 · Cited by 184
Independent prognostic factors for AML outcome
Grimwade, D., & Hills, R. K. (2009) · Hematology · doi:10.1182/asheducation-2009.1.385 · Cited by 180
Self-citationMaurillo, L., Buccisano, F., Del Principe, M. I., Del Poeta, G., Spagnoli, A., Panetta, P., Ammatuna, E., Neri, B., Ottaviani, L., Sarlo, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9814 · Cited by 179
Langebrake, C., Creutzig, U., Dworzak, M. N., Hrušák, O., Mejstříková, E., Griesinger, F., Zimmermann, M., & Reinhardt, D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4312 · Cited by 156
van der Velden, V. H. J., van der Sluijs‐Gelling, A. J., Gibson, B. E. S., Marvelde, J. G. T., Hoogeveen, P. G., Hop, W. C. J., Wheatley, K., Bierings, M., Schuurhuis, G. J., de Graaf, S. S. N., et al. (2010) · Leukemia · doi:10.1038/leu.2010.153 · Cited by 143
Ommen, H. B., Schnittger, S., Jovanovic, J. V., Ommen, I. B., Hasle, H., Østergaard, M., Grimwade, D. J., & Hokland, P. (2009) · Blood · doi:10.1182/blood-2009-04-212530 · Cited by 143
Self-citationBuccisano, F., Maurillo, L., Gattei, V., Poeta, G. D., Principe, M. I. D., Cox, M. C., Panetta, P., Consalvo, M. I., Mazzone, C., Neri, B., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404313 · Cited by 131
Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms
Ossenkoppele, G. J., van de Loosdrecht, A. A., & Schuurhuis, G. J. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08595.x · Cited by 117
Monitoring of minimal residual disease in acute myeloid leukemia
Kern, W., Haferlach, C., Haferlach, T., & Schnittger, S. (2007) · Cancer · doi:10.1002/cncr.23128 · Cited by 112
Minimal residual disease in acute myeloid leukemia: coming of age
Paietta, E. M. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.35.3797926 · Cited by 109
Development of Minimal Residual Disease–Directed Therapy in Acute Myeloid Leukemia
Freeman, S. D., Jovanovic, J. V., & Grimwade, D. J. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.009 · Cited by 99
Self-citationBachas, C., Schuurhuis, G. J., Assaraf, Y. G., Kwidama, Z. J., Kelder, A., Wouters, F., Snel, A. N., Kaspers, G. J. L., & Cloos, J. J. (2012) · Leukemia · doi:10.1038/leu.2011.383 · Cited by 98
Westers, T. M., Alhan, C., Chamuleau, M. E. D., van der Vorst, M. J. D. L., Eeltink, C., Ossenkoppele, G. J., & van de Loosdrecht, A. A. (2009) · Blood · doi:10.1182/blood-2009-08-239749 · Cited by 92
Assessment of minimal residual disease in acute myeloid leukemia
Grimwade, D. J., Vyas, P., & Freeman, S. D. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833ed831 · Cited by 81
Self-citationTowards individualized follow-up in adult acute myeloid leukemia in remission
Hokland, P., & Ommen, H. B. (2010) · Blood · doi:10.1182/blood-2010-09-303685 · Cited by 80
Decoupling of Tumor-Initiating Activity from Stable Immunophenotype in HoxA9-Meis1-Driven AML
Gibbs, K. D., Jager, A., Crespo, O., Goltsev, Y., Trejo, A., Richard, C., & Nolan, G. P. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.01.004 · Cited by 64
Varricchio, L., Masselli, E., Alfani, E., Battistini, A., Migliaccio, G., Vannucchi, A. M., Zhang, W., Rondelli, D., Godbold, J., Ghinassi, B., et al. (2011) · Blood · doi:10.1182/blood-2010-07-296921 · Cited by 47
Godley, L. A. (2012) · New England Journal of Medicine · doi:10.1056/nejme1200409 · Cited by 19
Cited by
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Self-citationDiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
Schuurhuis, G. J., Heuser, M., Freeman, S., Béné, M.-C., Buccisano, F., Cloos, J., Grimwade, D., Haferlach, T., Hills, R. K., Hourigan, C. S., et al. (2018) · Blood · doi:10.1182/blood-2017-09-801498 · Cited by 1,041
Self-citationShort, N. J., Rytting, M. E., & Cortes, J. E. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31041-9 · Cited by 781
Heuser, M., Freeman, S. D., Ossenkoppele, G. J., Buccisano, F., Hourigan, C. S., Ngai, L. L., Tettero, J. M., Bachas, C., Baer, C., Béné, M.-C., et al. (2021) · Blood · doi:10.1182/blood.2021013626 · Cited by 763
Self-citation
Metadata
- Authors
- Freeman, S. D., Virgo, P., Couzens, S., Grimwade, D., Russell, N., Hills, R. K., & Burnett, A. K.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-11-10
- Volume
- 31
- Issue
- 32
- Pages
- 4123-4131
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2124159210
- Cited by
- 317
- References
- 46
- FWCI
- 17.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.